Research programme: antibacterials - Cumbre Pharmaceuticals
Alternative Names: Anti-tuberculosis agents research programme - Cumbre Pharmaceuticals; Antibacterials research programme - Cumbre Pharmaceuticals; CBR 703 series - Cumbre Pharmaceuticals; Research programme: RNA polymerase inhibitors - Cumbre Pharmaceuticals; RNA polymerase inhibitors research programme - Cumbre PharmaceuticalsLatest Information Update: 29 Dec 2009
At a glance
- Originator Cumbre Pharmaceuticals
- Class Amidines; Hydroxylamines
- Mechanism of Action DNA-directed RNA polymerase inhibitors; Protein synthesis inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Tuberculosis
Most Recent Events
- 23 Oct 2003 Preclinical trials in Bacterial infections in USA (unspecified route)
- 11 Mar 1999 Preclinical development for Bacterial infections in USA (Unknown route)